TNP-470
(Synonyms: O-(氯乙酰氨甲酰基)烟曲霉素醇,AGM-1470|O-(Chloroacetyl-carbamoyl) Fumagillol|NSC 642492) 目录号 : GC12732An inhibitor of angiogenesis
Cas No.:129298-91-5
Sample solution is provided at 25 µL, 10mM.
IC50: 2 μM
TNP-470 is a methionine aminopeptidase-2 (MetAP2) inhibitor.
MetAP2 is present in all organisms and is important due to its key role in tissue repair and protein degradation. Moreover, MetAP2 is of particular interest since it plays a critical role in angiogenesis, which is necessary for the progression of diseases, such as solid tumor cancers and rheumatoid arthritis.
In vitro: Antitumor activity of TNP-470 was evaluated in eight human cultured cell lines derived from choriocarcinoma; ovarian cancer; TYK and Nakajima; and uterine endometrial cancer. Results showed that after 7-day culture with TNP-470, in medium at the concentration of 10 to 10-2 μg/ml, the inhibition of growth was observed in all of the eight cell lines. The half inhibitory concentration of choriocarcinoma cell lines was at an extremely low level compared to that of e uterine endometrial cancer and pithelial ovarian cancer [1].
In vivo: The anti-tumor effect of TNP-470 was studied using nude mice with tumors of GCH-1(m), NUC-1, or Nakajima cells. When the size of the transplanted tumor reached 100–200 mm3, 3, 10, or 30 mg/kg of TNP-470 was injected every other day. It was found that the inhibitory effect of TNP-470 was obtained by the administration of 10 and 30 mg/kg in GCH-1(m) and NUC-1 cells, respectively, while in Nakajima cells there was no significant effect. In addition, in nude mice treated with 30 mg/kg of TNP-470, lung metastasis of GCH-1(m) cells was greatly inhibited both in the number and the size of tumor nodules, suggesting that the capillary growth in the originally developed tumor was also reduced [1].
Clinical trial: A phase I study found that the effects of TNP-470 could be evaluated in 32 of the 33 patients. The dose-limiting toxic effect was a characteristic neuropsychiatric symptom complex. No definite anti-tumor activity of TNP-470 was observed; however, transient stimulation of the serum prostate-specific antigen concentration occurred in some of the patients treated [2].
References:
[1] T. Yanase, M. Tamura, K. Rujita, et al. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Research 53(11), 2566-2570 (1993).
[2] C J Logothetis et al. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clinical Cancer Research 7(5):1198-203.
Cell experiment: | MTT assays are applied to test cell viability. In brief, 3×103 cells per well are seeded in a 96-well plate and incubated with various concentration of TNP-470 for 24, 48, and 72 h at 37°C, 5% CO2. For comparison, cells cultured in the absence of TNP-470 are used as a control. After an incubation period, 10 μL MTT (0.5 mg/mL final concentration) is added to each well. After 4 h of additional incubation, 100 μL of 0.01 N HCl in isopropanol is added to dissolve the crystals. Absorption at 570 nm is determined by ELISA plate reader[1]. |
Animal experiment: | Individually housed, 4 wk old male C57BL/6 mice are used in this study. After a 1 wk acclimation period, mice are randomly allocated to receive either standard chow diet or high-fat diet for 6.5 wk. Throughout the high-fat feeding period the mice are treated with TNP-470 at a dose of 20 mg/kg body weight, injected subcutaneously every other day (TNP; n=7) or a vehicle injection of an equivalent volume (HFF controls; n=7). Vehicle injections contain 3% ethanol in phosphate-buffered saline. Chow-fed control mice (chow; n=8) are sham injected. Mice are fed ad libitum with food replaced every 2 or 3 days. Body weights are collected three times per week. After 6.5 wk of feeding, animals are fasted for 16-h and sacrificed. Final body, liver, and epididymal adipose tissue weights are measured. Liver and adipose tissue samples are frozen in liquid nitrogen and stored at -80°C for subsequent analysis[2]. |
References: [1]. Kidoikhammouan S, et al. TNP-470, a methionine aminopeptidase-2 inhibitor, inhibits cell proliferation, migration and invasion of human cholangiocarcinoma cells in vitro. Asian Pac J Cancer Prev. 2012;13 Suppl:155-60. |
Cas No. | 129298-91-5 | SDF | |
别名 | O-(氯乙酰氨甲酰基)烟曲霉素醇,AGM-1470|O-(Chloroacetyl-carbamoyl) Fumagillol|NSC 642492 | ||
化学名 | (3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl]-1-oxaspiro[2.5]oct-6-yl ester N-(2-chloroacetyl)-carbamic acid | ||
Canonical SMILES | O=C(NC(CCl)=O)O[C@@H]1CC[C@@]2(OC2)[C@]([C@](O3)(C)[C@H]3C/C=C(C)/C)([H])[C@@H]1OC | ||
分子式 | C19H28ClNO6 | 分子量 | 401.9 |
溶解度 | ≤10mg/ml in ethanol;10mg/ml in DMSO;10mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.4882 mL | 12.4409 mL | 24.8818 mL |
5 mM | 0.4976 mL | 2.4882 mL | 4.9764 mL |
10 mM | 0.2488 mL | 1.2441 mL | 2.4882 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet